$EAPH Announces North American Products Distribution and Intellectual Property Agreement

TORONTO, ON–(Marketwired – Mar 19, 2015) – Easton Pharmaceuticals Inc. (OTC PINK: EAPH), (the “Company”) Announces it has executed a distribution and intellectual property agreement for its full range of OTC therapeutic and specialty products with NutraShop Global Stores, Inc. currently serving thousands of trusting online customers looking for Quality Life Wellness Products.

NutraShop Global Stores (https://www.nutrashopglobal.com) has been successfully selling online to customers for several years across North America who’s customer base are searching for high quality wellness products. NutraShop has established strong distribution channels that allow the company to sell house hold specialty brands for less. Many of the products sold online can also be found in major health and grocery stores across the United States and Canada, such as Wholefoods and Canada’s Loblaws Markets, a leading national grocery chain. NutraShop is currently one of only 2 online retailers to sell the MadeGood Foods brand as seen in every major grocery and health retailer across Canada in stores such as wholefoods with the soon anticipated entry in the much larger U.S. market.

NutraShop’s mandate is a global trend; Health and Wellness with Anti-Aging at the forefront without the side effects associated with mainstream drugs. With the push to look better, feel better and live longer healthier lives, NutraShop now features Easton’s new line of wellness products including a cosmetic grade Anti-Aging serum, Pain Relief Gel and a Female Health product that each independently offer pharmaceutical grade efficacy while clinically proven safe and natural without the side effects that accompany many, if not all drugs. Online sales launch of Eaton’s 3 initial products are to be introduced and launched at the upcoming trade shows including the Total Health Show in mid April where attendance has been confirmed.

In addition to distributing Eastons OTC proprietary therapeutic products, Easton Pharmaceuticals has also provided Nutrashop rights and access to its transdermal delivery system and formulations that are to be utilized in new products being jointly developed, one of which includes a new children’s topical product containing exotic active ingredients to treat certain skin conditions.

NutraShop will compliment their existing road show by highlighting Eastons products over the next two months at the highly anticipated Yoga Show, Health Show and Mom Show throughout the greater Toronto region and upcoming U.S trade shows reaching audiences up to 125,000 looking for natural safe ways to improve health and vitality as well as new possible retail distribution channels.

Carla Pepe, CEO of Easton Pharmaceuticals, stated, “We have taken another significant step forward with distribution of our ready to launch OTC products to coincide with our operational retail Vaporizer business. Our new distribution agreement firmly puts our products on the map alongside several already established house hold brand names. This partnership will set the wheels in motion for the long awaited launch and sales of our OTC and therapeutic products as we showcase our products to customers looking for effective natural solutions online in the US and Canada and to thousands of people attending the upcoming trade shows.” Mrs. Pepe further commented, “Our partnership with NutraShop will enable us to not only further our customer reach, but to derive income and profit from the online sales and marketing of non-competitive consumer goods. Moreover, this partnership will help us gain valuable insight into online consumer sales behavior and trends that can only help our business in the future. Shareholders can also expect additional upcoming announcements including anticipated store locations.”

In other developments, Easton Pharmaceuticals is nearing the expected completion of a 50 / 50 joint venture partnership agreement to be an exclusive distributor in Mexico and all of Latin America and its over 400 Million population for a world patented diagnostic woman’s product that has in the past few months commenced sales in Walgreens and other drug stores in both the United States and Canada. Once an agreement has been finalized, the products, manufacturers and sales projections will be disclosed which is forecasted to generate significant, consistent and growing annual revenues protected by 12 year international patents.

About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously developed and owned an FDA approved wound healing drug and currently owns topically-delivered drugs and other therapeutic products that are all in various stages of development. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC assets; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their GroZone anti-microbial airflow system needed for growing pesticide free medicine, and currently have an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada in Port Perry, Ontario, which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:
https://www.nutrashopglobal.com
https://www.eastonpharmaceuticalsinc.com

https://ecigmarkets.com/
https://finance.yahoo.com/q?s=eaph

https://twitter.com/eastonpharma
https://www.grozone.biz

Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope,” “positive,” “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.